



UC061.1CP1CP

PATENT
RECEIVED

OCT 29 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Ameae Walker) Group Art Unit 1647 TECH CENTER 1600/2900
Appl. No.	:	09/065,330)
Filed	:	April 23, 1998) I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: United States Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202, on
For	:	PROLACTIN ANTAGONISTS AND USES THEREOF) <u>September 20, 2002</u> (Date)
Examiner	:	Christine J. Saoud) <u>Ginger R. Dreger</u> Ginger R. Dreger, Reg. No. 33,055

RESPONSE TO FINAL OFFICE ACTION

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202
ATTENTION BOX: AF

Dear Sir:

In response to the Final Office Action (Paper No. 30), dated June 21, 2002, setting a three-months term for response, please consider the following remarks.

REMARKS

Claims 1-6 and 9-11 are pending in this application.

Rejections under 35 U.S.C. § 103

Claims 1-6 and 9-11 were rejected under 35 U.S.C. 103(a) "as being unpatentable over the combination of Cooke et al. (U.S. Pat. No. 4,725,549) and A.M. Walker (TEM, 5(5): 195-200) in view of Maciejewski et al. (J. Biol. Chem. 270(17): 27661-27665, 1995, for the reasons of record in paper #13, 16 and 25."

Cooke et al. was cited by the Examiner for its teaching of recombinant prolactin. Walker was cited by the Examiner "for the teaching that a serine in prolactin within the region of amino